China lifts price caps on 1,500 drugs

05/11/2014 | Reuters

China's National Development and Reform Commission lowered from more than 2,000 to about 500 the number of drugs considered critical to health and subject to low-price caps. The commission noted that low prices have limited manufacturers' ability to absorb rising costs and caused shortages of some medicines. The commission has not announced the results of its yearlong investigation into the pricing practices of Chinese and international pharmaceutical firms.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI